Drug Resistance Related To Aberrant Glycosylation In Colorectal Cancer
Ninon Very, Tony Lefebvre, Ikram El Yazidi-Belkoura
Published 2018 · Medicine
Download PDFAnalyze on Scholarcy
Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths in the world. Drug resistance of tumour cells remains the main challenge toward curative treatments efficiency. Several epidemiologic studies link emergence and recurrence of this cancer to metabolic disorders. Glycosylation that modifies more than 80% of human proteins is one of the most widepread nutrient-sensitive post-translational modifications. Aberrant glycosylation participates in the development and progression of cancer. Thus, some of these glycan changes like carbohydrate antigen CA 19-9 (sialyl Lewis a, sLea) or those found on carcinoembryonic antigen (CEA) are already used as clinical biomarkers to detect and monitor CRC. The current review highlights emerging evidences accumulated mainly during the last decade that establish the role played by altered glycosylations in CRC drug resistance mechanisms that induce resistance to apoptosis and activation of signaling pathways, alter drug absorption and metabolism, and led to stemness acquisition. Knowledge in this field of investigation could aid to the development of better therapeutic approaches with new predictive biomarkers and targets tied in with adapted diet.
This paper references
A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency#
Sun Tian (2012)
A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases
M Ychou (2013)
Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents.
Evellyne de Oliveira Figueirôa (2017)
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
Danielle H Dube (2005)
Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.
Eric P. Bennett (2012)
Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells
Ying-Chih Liu (2011)
A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation.
Henrik Clausen (1996)
Loss of Disialyl Lewisa, the Ligand for Lymphocyte Inhibitory Receptor Sialic Acid-Binding Immunoglobulin-Like Lectin-7 (Siglec-7) Associated with Increased Sialyl Lewisa Expression on Human Colon Cancers
Keiko Miyazaki (2004)
Cancer cell death induced by nanomagnetolectin.
Dina M M Alsadek (2017)
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy
Wey-Ran Lin (2016)
Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon.
Nadia Malagolini (2007)
α(1,2)fucosylation in human colorectal carcinoma.
Laura Muinelo-Romay (2010)
Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia.
Bernard J. Fernandes (1991)
Serum-stimulated cell cycle entry promotes ncOGT synthesis required for cyclin D expression
Stéphanie Olivier-Van Stichelen (2012)
P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting
Prashanth Gokare (2017)
OGT: a short overview of an enzyme standing out from usual glycosyltransferases.
Moyira Osny Aquino-Gil (2017)
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer
Joseph P. Balint (2015)
Phosphorylation of thymidylate synthase from various sources by human protein kinase CK2 and its catalytic subunits.
Tomasz Frączyk (2010)
O-GlcNAcylation and the Metabolic Shift in High-Proliferating Cells: All the Evidence Suggests that Sugars Dictate the Flux of Lipid Biogenesis in Tumor Processes
Steffi F. Baldini (2016)
O-glycan inhibitors generate aryl-glycans, induce apoptosis and lead to growth inhibition in colorectal cancer cell lines.
Georgios Patsos (2009)
Vertebrate protein glycosylation: diversity, synthesis and function
Kelley W. Moremen (2012)
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner (2007)
Mucins in normal and neoplastic human gastrointestinal tissues.
Thécla Lesuffleur (1994)
Mucins and mucin binding proteins in colorectal cancer
James Cozby Byrd (2004)
C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2
Ji-Shiang Hung (2014)
Induction of MUC2 and MUC5AC Mucins by Factors of the Epidermal Growth Factor (EGF) Family Is Mediated by EGF Receptor/Ras/Raf/Extracellular Signal-regulated Kinase Cascade and Sp1*
Michaël Perrais (2002)
β3GnT8 regulates the metastatic potential of colorectal carcinoma cells by altering the glycosylation of CD147.
Jianlong Ni (2014)
Phenotypic characterization of human colorectal cancer stem cells
Piero Dalerba (2007)
MUC1: a multifaceted oncoprotein with a key role in cancer progression.
Sritama Nath (2014)
Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy
Ten-i Godai (2009)
The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
Ranran Wang (2013)
Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc.
Claudia E. Rodriguez Torres (1984)
O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability
Xinwen Yang (2001)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton (2009)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi (2017)
Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility.
Innoc Han (1997)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Magaly Moroni (2005)
Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway
Eduardo Vilar (2009)
Glycosylation in cancer: mechanisms and clinical implications
Salomé S Pinho (2015)
Hyper-O-GlcNAcylation Is Anti-apoptotic and Maintains Constitutive NF-κB Activity in Pancreatic Cancer Cells*
Zhiyuan Ma (2013)
Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1α Activation in a Survival Response to Hypoxia*
Li Yin (2007)
Modification of topoisomerase I activity by glucose and by O-GlcNAcylation of the enzyme protein.
Noa Noach (2007)
Mechanisms of drug resistance in colon cancer and its therapeutic strategies.
Tao Hu (2016)
Glycosylation alterations of cells in late phase apoptosis from colon carcinomas.
E. M. Rapoport (1999)
Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers
Jishun Lu (2015)
The dynamic stress-induced “O-GlcNAc-ome” highlights functions for O-GlcNAc in regulating DNA damage/repair and other cellular pathways
Natasha Elizabeth Zachara (2010)
Modification of Sialylation Mediates the Invasive Properties and Chemosensitivity of Human Hepatocellular Carcinoma*
Yongfu Zhao (2013)
Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state.
Yoram Altschuler (2000)
Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation.
José Alexandre Ferreira (2016)
O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway.
Christina M. Ferrer (2014)
Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis
Kelly B. Stein (2009)
Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium.
Akio Takada (1993)
The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation.
Stéphanie Olivier-Van Stichelen (2012)
Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.
Caterina Fanali (2014)
Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Jung Jin Park (2012)
Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations.
Thécla Lesuffleur (1993)
Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer
Parunya Chaiyawat (2014)
Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours.
Ashish V. Kalra (2009)
Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine-type N-glycans.
Li Shen (2014)
Manipulating the apoptotic pathway: potential therapeutics for cancer patients.
Darcy J. P. Bates (2013)
Elevation of an alpha(1,3)fucosyltransferase activity correlated with apoptosis in the human colon adenocarcinoma cell line, HT-29
S Akamatsu (1996)
Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo.
Felipe de Melo Santos (2011)
Elevated glucose levels impair the WNT/β-catenin pathway via the activation of the hexosamine biosynthesis pathway in endometrial cancer
Fuxing Zhou (2016)
Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics
Q. D. Lin (2010)
Distribution of blood group antigens A, B, H, Lewisa, and Lewisb in human normal, fetal, and malignant colonic tissue.
Ming Fung Yuan (1985)
O-GlcNAcylation and chromatin remodeling in mammals: an up-to-date overview.
Maïté Leturcq (2017)
The role of Nglycans in colorectal cancer progression : potential biomarkers and therapeutic applications
JC deFreitasJunior (2016)
Mucin-Type O-Glycosylation in Gastric Carcinogenesis
Henrique Duarte (2016)
Glycans in cancer and inflammationfor therapeutics and diagnostics
DH Dube (2005)
Sialylation of the Fas Death Receptor by ST6Gal-I Provides Protection against Fas-mediated Apoptosis in Colon Carcinoma Cells*
Amanda F. Swindall (2011)
Ras oncogene directs expression of a differentially sialylated, functionally altered β1 integrin
Eric C. Seales (2003)
A little sugar goes a long way: The cell biology of O-GlcNAc
Michelle R. Bond (2015)
On respiratory impairment in cancer
O. Warburg (1956)
Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)
Bhawna Bagaria (2013)
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Patrice J. Morin (1997)
The E2F-1 associated retinoblastoma-susceptibility gene product is modified by O-GlcNAc
Lance Wells (2010)
Glycosylation-directed quality control of protein folding
Chengchao Xu (2015)
Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens.
Kazuo Kamemura (2002)
Cellular glycosylation senses metabolic changes and modulates cell plasticity during epithelial to mesenchymal transition.
Patricia Carvalho-Cruz (2018)
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
Harri M Itkonen (2013)
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
Sean C. Glasgow (2005)
Silencing β-linked N-acetylglucosamine transferase induces apoptosis in human gastric cancer cells through PUMA and caspase-3 pathways.
Ti Wen (2015)
Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis.
Kazutaka Murata (2000)
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
Megan C. Duggan (2016)
MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target
Yong Hua Sheng (2017)
A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial
Marc Ychou (2013)
Inhibition of CD147 expression by RNA interference reduces proliferation, invasion and increases chemosensitivity in cancer stem cell-like HT-29 cells.
Jie Chen (2015)
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes
Yoko Yanagisawa (2007)
Significance of β-Galactoside α2
Protein O-GlcNAcylation: emerging mechanisms and functions
Xiaoyong Yang (2017)
Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues.
Fabio Dall'Olio (1989)
ST6Gal-I Regulates Macrophage Apoptosis via α2-6 Sialylation of the TNFR1 Death Receptor*
Zhongyu Liu (2011)
Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression
Balázs Bánky (2012)
Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma.
Tomohiro Nakayama (1995)
Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial.
Vassiliki L Tsikitis (2009)
Dynamic O-GlcNAc Modification of Nucleocytoplasmic Proteins in Response to Stress
Natasha Elizabeth Zachara (2004)
Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer.
Steven H. Itzkowitz (1989)
Pharmacologic resistance in colorectal cancer: a review
William A. Hammond (2016)
Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
Toshie Iwai (2005)
O-GlcNAcylation stabilizes β-catenin through direct competition with phosphorylation at threonine 41.
Stéphanie Olivier-Van Stichelen (2014)
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.
Ralph J. DeBerardinis (2008)
The Risk of Colorectal Cancer in Patients With Type 2 Diabetes: Associations With Treatment Stage and Obesity
Paul J. Peeters (2014)
The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications
Julio Cesar Madureira de Freitas Junior (2016)
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Beatrice Mohelníková-Duchoňová (2014)
MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147
Lipan Peng (2015)
[Origin of cancer cells].
Otto Heinrich Warburg (1956)
Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines
Jun Hamaguchi (2007)
alpha1,2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells.
Caroline Goupille (2000)
MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.
Shoji Nakamori (1994)
Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons
William H Gmeiner (2010)
Understanding the colon cancer stem cells and perspectives on treatment
Elsa Nancy Garza-Treviño (2015)
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
Lioe-Fee de Geus-Oei (2009)
Aberrant α1→2Fucosyltransferases Found in Human Colorectal Carcinoma Involved in the Accumulation of Leb and Y Antigens in Colorectal Tumors
Shin Yazawa (1993)
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines.
J Sakamoto (1986)
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay (2015)
Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization.
J P Audié (1993)
Invasion and Metastasis in Colorectal Cancer: Epithelial-Mesenchymal Transition, Mesenchymal-Epithelial Transition, Stem Cells and β-Catenin
Thomas Brabletz (2005)
Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis.
Ya Zhuo (2008)
Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer.
Voraratt Champattanachai (2013)
O-Linked N-Acetylglucosamine (O-GlcNAc) Expression Levels Epigenetically Regulate Colon Cancer Tumorigenesis by Affecting the Cancer Stem Cell Compartment via Modulating Expression of Transcriptional Factor MYBL1*
Huabei Guo (2017)
Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells
Francesca Pepe (2017)
Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors
Mériam Ayadi (2015)
Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation.
Stéphan Hardivillé (2014)
Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes
Kekoa Taparra (2016)
Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
Tao Xu (2014)
MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
Florence Renaud (2015)
Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer.
Margarita González-Vallinas (2015)
Ras oncogene directs expression of a differentially sialylated, functionally altered beta1
EC Seales (2003)
Sd(a)-antigen-like structures carried on core 3 are prominent features of glycans from the mucin of normal human descending colon.
Claire Capon (2001)
N Dubrawsky (1989)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Andrea Sartore-Bianchi (2007)
MUC1 Oncoprotein Activates the FOXO3a Transcription Factor in a Survival Response to Oxidative Stress*
Li Yin (2004)
Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention
Lin Zhang (2013)
Heterogeneity of mucin gene expression in normal and neoplastic tissues.
Samuel B. Ho (1993)
Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients
Michael Morse (2015)
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer
Alejandro J. Cagnoni (2016)
Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients.
Mario Lise (2000)
O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer.
Fabienne Vavasseur (1994)
Sialyltranferase 1 in Cancers
Modulation of O-LinkedN-Acetylglucosamine Levels on Nuclear and Cytoplasmic Proteins in Vivo Using the PeptideO-GlcNAc-β-N-acetylglucosaminidase InhibitorO-(2-Acetamido-2-deoxy-dglucopyranosylidene)amino-N-phenylcarbamate*
Robert S. Haltiwanger (1998)
UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V.
Ken Sasai (2002)
THE ORIGIN OF CANCER.
Cuthbert E. Dukes (1938)
Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions.
J Sun (2001)
Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2
Olaf H. Temmink (2010)
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Patrick Yaffee (2015)
Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis
Akira Konno (2004)
Nutrient sensor OGlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM 1
SA Caldwell (2010)
Silencing the Nucleocytoplasmic O-GlcNAc Transferase Reduces Proliferation, Adhesion, and Migration of Cancer and Fetal Human Colon Cell Lines
Agata Steenackers (2016)
Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells.
Pietro Vella (2013)
Tumor-related expression of alpha1,2fucosylated antigens on colorectal carcinoma cells and its suppression by cell-mediated priming using sugar acceptors for alpha1,2fucosyltransferase.
Shin Yazawa (2002)
Biological properties and expression of mucins in 5-fluorouracil resistant HT29 human colon cancer cells.
So Rae Choi (2000)
Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types.
Miri Blank (1994)
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells
Kyoung Ah Kang (2016)
Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN
J Ferlay (2012)
Early detachment of colon carcinoma cells during CD95(APO-1/Fas)- mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44
Andreas R. Günthert (1996)
Beta1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity.
Hirotsugu Yamamoto (2000)
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Jeffrey A. Meyerhardt (2006)
An Oncogenic Protein Golgi Phosphoprotein 3 Up-regulates Cell Migration via Sialylation*
Tomoya Isaji (2014)
The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential.
Florence Renaud (2016)
O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy.
Wenyi Mi (2011)
On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database.
Rolf Apweiler (1999)
Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer.
Mineko Izawa (2000)
Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.
Hiroshi Nakagawa (2009)
Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
John Nemunaitis (2013)
2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells
C Goupille (2000)
How cancer metabolism is tuned for proliferation and vulnerable to disruption
Almut Schulze (2012)
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Chau-Ting Yeh (2014)
ABH and Lewis histo-blood group antigens in cancer.
Jacques Le Pendu (2001)
Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability
Won Ho Yang (2006)
Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer.
Naoki Mashita (2014)
Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
Diego O. Croci (2014)
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.
Jian Ren (2004)
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
James J. Dignam (2006)
Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer.
Thanong Phueaouan (2013)
Differential expression of difucosyl type 2 chain (LeY) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas.
Koichiro Abe (1986)
Studies on L-glutamine D-fructose 6-phosphate amidotransferase. I. Feedback inhibition by uridine diphosphate-N-acetylglucosamine.
Rosalind Kornfeld (1967)
Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil.
Sandrine Cordel (2000)
Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility.
Eric C. Seales (2005)
Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer
Andréia Vasconcelos-dos-Santos (2015)
CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
Wassili Jansen (1997)
Ten-Eleven Translocation 1 (Tet1) Is Regulated by O-Linked N-Acetylglucosamine Transferase (Ogt) for Target Gene Repression in Mouse Embryonic Stem Cells*
F Shi (2013)
O-GlcNAcylation: A New Cancer Hallmark?
Yann Fardini (2013)
Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.
Gerald W. Hart (2011)
Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1
Sarah A. Caldwell (2010)
Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer
Srividya Venkitachalam (2016)
Regulation of CK2 by Phosphorylation and O-GlcNAcylation Revealed by Semisynthesis
Mary Katherine Tarrant (2012)
C2GnTM is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells
MC Huang (2006)
Fernández-Briera A. α(1,2)fucosylation in human colorectal carcinoma
L Muinelo-Romay (2010)
On respiratory impairment in cancer cells.
Sidney Weinhouse (1956)
Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.
Shiv Ram Krishn (2016)
Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype
Michael D. Walsh (2013)
[Genetic alterations in colorectal cancer].
Pierre Laurent-Puig (1994)
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Jeffrey A. Meyerhardt (2012)
Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition.
Sang Yoon Park (2010)
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status
P. García-Alfonso (2014)
ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.
Amanda F. Swindall (2013)
O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation.
Gerald W. Hart (1995)
A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer.
Hiroyasu Ishida (2005)
This paper is referenced by
Truncated O‐glycans promote epithelial‐to‐mesenchymal transition and stemness properties of pancreatic cancer cells
Divya Thomas (2019)
protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases.
Xavier Verhelst (2019)
Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation
Yilin Chen (2018)
Targeted delivery of poly (methyl methacrylate) particles in colon cancer cells selectively attenuates cancer cell proliferation
Firdos Alam Khan (2019)
A fucosyltransferase inhibition assay using image-analysis and digital microfluidics.
Laura Leclerc (2019)
Cell surface CD63 increased by up-regulated polylactosamine modification sensitizes human melanoma cells to the BRAF inhibitor PLX4032.
Kohya Kudo (2019)
Impact of gastrointestinal physiology on drug absorption in special populations - An UNGAP review.
Cordula Stillhart (2020)
OGT Controls the Expression and the Glycosylation of E-cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines.
James Biwi (2019)
Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology
Elisabete Fernandes (2020)
O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer.
Sheue-Fen Tzeng (2018)
The Many Ways by Which O-GlcNAcylation May Orchestrate the Diversity of Complex Glycosylations
James Biwi (2018)
Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation
Jian Wu (2018)
New Lectins from Mediterranean Flora. Activity against HT29 Colon Cancer Cells
Isabel Oliveira (2019)
Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase
Xin Yu Koh (2019)
Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis
Simon Bousseau (2018)
Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents
Yueqin Yang (2020)
Tunicamycin induces ER stress and inhibits tumorigenesis of head and neck cancer cells by inhibiting N-glycosylation.
Yang Wang (2020)
Fucose-Galactose Polymers Inhibit Cholera Toxin Binding to Fucosylated Structures and Galactose-Dependent Intoxication of Human Enteroids
Jakob Cervin (2020)
Modulation of CD95-mediated signaling by post-translational modifications: towards understanding CD95 signaling networks
Kamil Seyrek (2019)